ReviewFrontiers in immunology2019
Complementing the Cancer-Immunity Cycle.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 211 citations in OpenAlex.
- Exploring shared biomarkers and their mechanisms in thyroid cancer and systemic lupus erythematosus via bioinformatics analysis.Discover oncology · 2026Article
- Liposomes in tumor treatment: a double-edged sword.Science China. Life sciences · 2026Review
- Neoantigens and shared MICB α3 antigen dual-targeted vaccine generates potent antitumor immunity.EMBO molecular medicine · 2026Article
- Trimethylamine-producing microbe Bacillus megaterium KCTC 3007 promotes antitumor immunity in endometrial cancer via type I interferon response pathways.Microbiome · 2026Article
- Progress in perioperative immunotherapy for lung cancer and analysis of therapy (Review).Oncology letters · 2026Review
- Understanding the role of C5a/C5aR1-mediated complement activation pathway in tumor progression and therapy resistance.Science China. Life sciences · 2026Review
- Article
- Macroscopic fractal dynamics characterize the "physical-metabolic" dual barriers and systemic immune exhaustion associated with primary resistance to immunotherapy in liver metastases.Frontiers in immunology · 2026Article
- IgE based therapeutics are an emerging modality in cancer treatment.Discover oncology · 2025Review
- Beyond the tumor: the gut microbiome as a key player in immunotherapy efficacy and resistance.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Serum from patients with oral squamous cell carcinoma remodels the tumor immune escape ecological niche by promoting regulatory T‑cell differentiation and T‑cell exhaustion.Oncology reports · 2025Article
- Recent Advances in the Application of Cucurbitacin B as an Anticancer Agent.International journal of molecular sciences · 2025Review
- Gaming the cancer-immunity cycle by synchronizing the dose schedules.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Cell Surface Proteomics Reveals Hypoxia-Regulated Pathways in Cervical and Bladder Cancer.Proteomes · 2025Article
- Engineering strategies of sequential drug delivery systems for combination tumor immunotherapy.Acta pharmaceutica Sinica. B · 2025Review
- Qingrehuoxue formula enhances anti-PD-1 immunotherapy in NSCLC by remodeling the tumor immune microenvironment via TREM2 signaling.BMC complementary medicine and therapies · 2025Article
- Controlling T cell-tumor cell interaction with a biomimetic physical barrier for cancer immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Identification of prostate cancer potential therapeutic targets and virtual drug screening through combined Mendelian randomization study, Bayesian colocalization and molecular docking.Discover oncology · 2025Article
- C5a/C5aR pathway blocking promoted CuS-mediated cancer therapy effect by inhibiting cuproptosis resistance.Journal for immunotherapy of cancer · 2025Article
- Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications.Journal for immunotherapy of cancer · 2025Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
Abstract
Reactivation of cytotoxic CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.